Life Sciences

Boston Scientific said last week its surgical treatment of Parkinson's disease has been found to improve motor scores and decrease medication usage.

Karyopharm Therapeutics has received conditional approval from the U.S. Food and Drug Administration for Verdinexor, its oral treatment of canine lymphoma.

A neonatal screening device made by Milford-based Waters Corp. has secured regulatory approval in China, clearing the way for promotion and sale in that country, the company announced.

Genzyme said its multiple sclerosis treatment, Lemtrada, has been recommended for reimbursement in the United Kingdom's health care system.

Franklin is as ready as it can possibly be for biotechnology companies, according to a statewide industry group.

Natick pharmaceutical company Karyopharm Therapeutics said its leading drug candidate has received federal designation as an “orphan drug” to help treat acute myeloid leukemia (AML).

On the heels of its recently announced acquisition of IoGyn Inc., Natick-based pharmaceutical company Boston Scientific Corp. (BSX) announced it will acquire the Interventional Division of Bayer AG for $415 million in cash.

RXi Pharmaceuticals Corp., a clinical-stage biotechnology company based in Marlborough, narrowed its net loss to $2.28 million in the first quarter, down from $14.39 million a year earlier.

Boston Scientific said it received a subpoena last week from federal regulators, seeking documents about some of its heart devices.

Massachusetts Life Sciences Center CEO Susan Windham-Bannister plans to wind down her tenure as head of the quasi-public business development agency over the coming months after six years at the helm during a boom period for life sciences in Massachusetts.